D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia
about
Risperidone versus other atypical antipsychotics for schizophreniaOlanzapine versus other atypical antipsychotics for schizophreniad-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophreniaClozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytesA novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypal personality disorder: altered l-serine level associated with disruption of PSAT1 gene expressionCurrent perspectives in the treatment of resistant schizophreniaThe impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophreniaIn vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophreniaProof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophreniaMeta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophreniaA randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophreniaHas an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophreniaEffects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategyGABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implicationsGlutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion.Allosteric modulation of metabotropic glutamate receptors.Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery.Neonatal disruption of serine racemase causes schizophrenia-like behavioral abnormalities in adulthood: clinical rescue by d-serineSex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.Effect of amphetamine on extracellular concentrations of amino acids in striatum in neurotensin subtype 1 and 2 receptor null mice: a possible interaction between neurotensin receptors and amino acid systems for study of schizophrenia.Research in people with psychosis risk syndrome: a review of the current evidence and future directionsGenetic loss of D-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice.Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model.Targeted disruption of serine racemase affects glutamatergic neurotransmission and behaviorPhencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors.Acute D-serine treatment produces antidepressant-like effects in rodentsClinical and biochemical study of d-serine metabolism among schizophrenia patients.Theranostic Biomarkers for SchizophreniaPotential role of the combination of galantamine and memantine to improve cognition in schizophreniaWhy is D-serine nephrotoxic and alpha-aminoisobutyric acid protective?D-serine treatment reduces cocaine-primed reinstatement in rats following extended access to cocaine self-administration.Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission.Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.Brain-specific Phgdh deletion reveals a pivotal role for L-serine biosynthesis in controlling the level of D-serine, an N-methyl-D-aspartate receptor co-agonist, in adult brain.Paliperidone: the evidence of its therapeutic value in schizophrenia.Glutamatergic model psychoses: prediction error, learning, and inferenceComparing genes and phenomenology in the major psychoses: schizophrenia and bipolar 1 disorder.Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia.
P2860
Q24234950-4CACC2C6-0743-41B9-A1CE-48ABF81A66F5Q24236545-66D49539-6C41-4B53-B048-55F9AD05EE53Q24294371-8FC26FFF-67B5-4A00-8007-76090064B813Q24606088-C447A5DA-0E09-4889-8362-15D6D6A11136Q24607731-00E2B936-DD6D-438F-9C86-26346E8F8796Q24650594-77AACCAF-74C1-4DD9-8CF9-A2F29A07A0D7Q28081110-53394D71-20BC-4D25-A990-0CE9C36C751FQ28083121-36773889-71EA-48B2-8312-91FECDB9F24AQ28240120-FBD569B0-7C99-46AC-A5E8-E6BDF3B23000Q28248687-FFBB3690-29B0-47A9-8E93-93560D7AD703Q28263502-C6CB4DB3-CC33-4760-B9D3-FBD3CE81FE4DQ28275290-C7CE8C21-2716-4D1C-908E-E1BF2D9D0208Q30355399-E22A4EFE-B3AD-4273-A75B-D432E056DC04Q30376372-76193BDB-5E76-405D-A2E0-AB722D489F4FQ30387014-7AFCDFDF-EEBC-44E1-91E7-F7038F4399EFQ30447828-9FEEE192-0723-4CE5-ABDC-13A48CC951FBQ30448534-A9783931-EC8E-49B0-AF4E-B6551D3F0410Q30454958-0E0D065E-9462-4143-81BF-817838345FD1Q30455182-75FC9BF5-8246-4A01-ACD1-F6B53DB39BE4Q30474007-391E94E1-B7A7-4F1A-A9DC-77B847B8CE3EQ30475349-82BFE1CA-993B-4077-AAAE-07402B431FB3Q30475598-CE83A7E6-346B-4243-B87F-440DD01BB95AQ30477241-D713F894-58DC-44B6-AA6F-2CE0EDEB6E40Q30479725-B2DDBF04-99D6-4A19-84AC-9C752CC9FAB8Q30484413-6D103232-9775-48AC-A9C6-E688E2CEB206Q30491856-CA1D76C9-6204-4541-B967-59394A3AFA0EQ30505292-400BE9BD-72EC-4655-A1E5-D01D1C31C305Q33565101-1E229E00-D1B3-4758-89FF-B132B4A7A3DCQ33624412-FDD12A80-86BA-425D-8392-3D290064B94AQ33905343-A6920C80-8613-4659-A1B6-0C5FE7A7937CQ34003528-2BEE29A3-8704-43C0-AC40-98B383FCF21AQ34036997-3D9F919E-2F96-4234-B451-891484D4BBA8Q34230984-2E333713-A0A8-4975-A2A0-DB25EB5ECB1DQ34330678-E66975DE-9359-4F7E-A815-831691FFE6C2Q34438746-1E0EBF98-75D9-4A6C-B0E8-86EB46291833Q34449894-3DB5A566-5171-4FBE-8A7B-8C718AC98F2DQ34661231-243ABBAA-B6A2-47CD-967B-62FAB82C38D4Q34783324-0C493BA0-2173-43BD-A347-858D5F13C9E2Q34926526-656DFA46-5DA6-4479-BB7A-360A8B461D4EQ34970798-40C625F8-2FDE-4A06-95C2-53668B2AB475
P2860
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
D-serine efficacy as add-on ph ...... tment-refractory schizophrenia
@ast
D-serine efficacy as add-on ph ...... tment-refractory schizophrenia
@en
D-serine efficacy as add-on ph ...... tment-refractory schizophrenia
@nl
type
label
D-serine efficacy as add-on ph ...... tment-refractory schizophrenia
@ast
D-serine efficacy as add-on ph ...... tment-refractory schizophrenia
@en
D-serine efficacy as add-on ph ...... tment-refractory schizophrenia
@nl
prefLabel
D-serine efficacy as add-on ph ...... tment-refractory schizophrenia
@ast
D-serine efficacy as add-on ph ...... tment-refractory schizophrenia
@en
D-serine efficacy as add-on ph ...... tment-refractory schizophrenia
@nl
P2093
P3181
P1476
D-serine efficacy as add-on ph ...... tment-refractory schizophrenia
@en
P2093
Agnes Vass
Marina Ermilov
Pesach Lichtenberg
Sara Catinari
Uriel Heresco-Levy
P304
P3181
P356
10.1016/J.BIOPSYCH.2004.12.037
P407
P577
2005-03-15T00:00:00Z